Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Pulmonary Surfactant Disorders and Lipid Transport Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for ABCA3 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Gene Delivery | ABCA3 Promise-ORF / Lentivirus Full-length ORF for stable alveolar cell line construction. Sequence Verified. |
View ABCA3 Products |
| Antigen (Soluble Domains) | ABCA3 NBD (Nucleotide-Binding Domain) Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Optimized for ATPase assays. |
View ABCA3 Products |
| Benchmark Ab | Anti-ABCA3 Recombinant Antibody Sequence-verified control for flow cytometry and expression profiling. |
View ABCA3 Products |
| Validator | ABCA3 siRNA Set For specific knockdown verification in functional lipid assays. |
View ABCA3 Products |
| Related Target A | SFTPC Surfactant Protein C, co-secreted with ABCA3-mediated lipids; crucial for pulmonary function networks. |
View SFTPC Products |
| Related Target B | ABCA1 Cholesterol efflux regulatory protein; key homology reference for ABC transporter selectivity profiling. |
View ABCA1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Complex Multi-pass Transmembrane Folding | Premade Lentivirus for in vitro stable cell line generation, preserving native membrane conformation. |
| Intracellular Domain Drug Screening | Truncated high-purity Nucleotide-Binding Domains (NBDs) specifically expressed for small molecule binding assays. |
| Lack of Reliable Expression Controls | Sequence-verified Recombinant Antibodies ensuring high specificity without batch-to-batch variation. |
| In Vitro Assay False Positives | Target-specific validated siRNA sets included for rigorous background subtraction and specificity checks. |
Live ABCA3 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for ABCA3 therapeutics is intensifying, driven by the critical need to address pediatric interstitial lung disease (chILD) and fatal surfactant deficiencies. While historically considered undruggable due to its complex 12-transmembrane structure, modern R&D is shifting focus from symptomatic treatment to small molecule "correctors" and "potentiators"—mirroring the cystic fibrosis (CFTR) breakthrough model. Furthermore, next-generation modalities like AAV-mediated gene therapy and LNP-mRNA replacement strategies are rapidly advancing into preclinical validation, aiming to restore functional ABCA3 expression directly in alveolar type II cells.
Competitive Modality & Indication Snapshot
| Modality | Representative Focus | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Modulators | Academic Consortia, Rare Disease Biotechs | chILD, Surfactant Deficiency | ATPase Activity Assays (Requires High-Purity NBD Recombinant Proteins) |
| Gene Therapy (AAV/Lenti) | Gene Editing Pioneers | Neonatal Respiratory Distress | Expression Validation (Requires Full-length ORF Lentivirus & Benchmark Abs) |
| mRNA / LNP Delivery | Pulmonary Delivery Specialists | Genetic Lung Diseases | In vitro cellular uptake & functional rescue (Requires Stable Cell Lines) |